OncoMatch/Clinical Trials/NCT05536141
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Official title: A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors
Is NCT05536141 recruiting? Yes, currently enrolling (Oct 2026). This Phase 1 trial studies multiple treatments including casdatifan and Cabozantinib for clear cell renal cell carcinoma.
Treatment: casdatifan · Cabozantinib · Zimberelimab · Ipilimumab — The purpose of this study is to evaluate the safety and tolerability of: * casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and * casdatifan monotherapy and casdatifan in combination with cabozantinib or zimberelimab or zimberelimab and ipilimumab in participants with ccRCC in the dose expansion stage.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Other
Cancer type
Renal Cell Carcinoma
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: hypoxia inducible factor (HIF)-2α inhibitor
prior treatment with an hypoxia inducible factor (HIF)-2α inhibitor
Cannot have received: (cabozantinib)
For the casdatifan + cabozantinib combination cohort, any prior treatment with cabozantinib
Cannot have received: systemic treatment
For casdatifan + zimberelimab and casdatifan + zimberelimab + ipilimumab cohorts, any prior systemic treatment when cancer is present
Lab requirements
Kidney function
creatinine clearance ≥ 40 ml/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham · Birmingham, Alabama
- University of California at San Diego · San Diego, California
- UCLA · Santa Monica, California
- University of Miami · Miami, Florida
- Emory University · Atlanta, Georgia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05536141 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior hypoxia inducible factor (HIF)-2α inhibitor, , systemic treatment disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages